| Biomarker ID | 577 |
| PMID | 21166384 |
| Year | 2011 |
| Biomarker | Apolipoprotein A-IV + Serum amyloid P-component + Gluthathione peroxidase 3 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include (GPX3):- Glutathione metabolism, Arachidonic acid metabolism Pathways Include(APP):- TAK1 activates NF-kappaB by phosphorylation and activation of IKK complex,TRAF6 mediated NF-kB activation,Inflammasomes,Platelet amyloid precursor protein pathway,Cytosolic sensors of pathogen-associated DNA |
| Experiment | BPH vs Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Out of total 50 patients, 18 with GS 5, 18 with GS 7 and 14 with BPH were identified. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.876 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | NMR |
| Clinical | No |
| Remarks | Random forest technique was applied to find a biomarker panel for 59 differentiated protiens.. Data shown for 10 fold cross validation. Improves performance over PSA (AUC= 0.374). 2D-DIGE performed better than NMR. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | APOA4, APP, GPX3 |